Evidence map›Paper›PMID 30348707›Full record

ArticleIn vivo (Athens, Greece)

Changes in HER2 Expression and Amplification Status Following Preoperative Chemotherapy for Gastric Cancer.

Sei Shu, Makoto Iimori, Ryota Nakanishi, Tomoko Jogo, Hiroshi Saeki, Eiji Oki, Yoshihiko Maehara

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  5. Article
  6. Article
  7. Investigation ofIranian journal of pathology · 2020
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Sei ShuDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Kyushu University, Fukuoka, Japan.
Makoto IimoriDepartment of Molecular Cancer Biology, Graduate School of Pharmaceutical Sciences, Kyushu University, Kyushu University, Fukuoka, Japan.
Ryota NakanishiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Kyushu University, Fukuoka, Japan.
Tomoko JogoDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Kyushu University, Fukuoka, Japan.
Hiroshi SaekiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Kyushu University, Fukuoka, Japan.
Eiji OkiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Kyushu University, Fukuoka, Japan okieiji@surg2.med.kyushu-u.ac.jp.
Yoshihiko MaeharaDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Kyushu University, Fukuoka, Japan.
Kyushu University · JPKyushu Central Hospital of the Mutual Aid Association of Public School Teachers · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt is essential to establish a strategy for second-line treatment for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer; however, HER2 expression status after chemotherapy treatment is not routinely determined. MATERIALS AND

methodsWe analyzed 25 cases of gastric cancer that received preoperative chemotherapy and selected the six pre-treatment samples that were HER2-positive. Pre- and post-treatment tumor samples were examined for HER2 expression, and for HER2, epidermal growth factor receptor (EGFR), and hepatocyte growth factor receptor (MET) gene amplification.

resultsThree patients had been treated with trastuzumab plus chemotherapy, and three patients with cytotoxic chemotherapy alone. Only one case that had an initial HER2 score of 3+ and had received trastuzumab plus chemotherapy remained HER2-positive after treatment. Decrease or loss of HER2 expression and amplification was observed in the other five patients. Amplification of EGFR or MET was not observed in any pre- or post-treatment specimens.

conclusionOur data suggest that trastuzumab plus chemotherapy or chemotherapy alone may induce loss of HER2 positivity.

Indexed as

AdultAgedBiomarkers, TumorCell ProliferationErb-b2 Receptor Tyrosine KinasesErbB ReceptorsFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMolecular Targeted TherapyPreoperative CareProto-Oncogene Proteins c-metStomach NeoplasmsTrastuzumabBiomarkers, TumorEGFR protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesErbB ReceptorsProto-Oncogene Proteins c-metTrastuzumabgastric cancerHER2trastuzumab

Identifiers

PMID30348707
PMCPMC6365720
OpenAlexW2896702220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.